Menu
Search
|

Menu

Close
X

Nektar Therapeutics NKTR.OQ (NASDAQ Stock Exchange Global Select Market)

38.19 USD
+0.54 (+1.43%)
As of 3:59 PM EST
chart
Previous Close 37.65
Open 37.41
Volume 845,446
3m Avg Volume 792,888
Today’s High 38.26
Today’s Low 35.98
52 Week High 111.36
52 Week Low 33.52
Shares Outstanding (mil) 173.09
Market Capitalization (mil) 6,464.73
Forward P/E 9.42
Dividend (Yield %) -- ( -- )

LATEST NEWS

ADVERTISEMENT

RECOMMENDATION

Sell Hold Buy
1.80 Mean rating from 10 analysts

KEY STATS

Revenue (mm, USD)
FY18
1,153
FY17
308
FY16
165
FY15
231
EPS (USD)
FY18
4.177
FY17
-0.640
FY16
-1.098
FY15
-0.616
*Note: Units in Millions of U.S. Dollars
**Note: Units in U.S. Dollars

KEY RATIOS

Price to Earnings (TTM)
vs sector
9.42
29.53
Price to Sales (TTM)
vs sector
5.18
22.95
Price to Book (MRQ)
vs sector
3.61
4.15
Price to Cash Flow (TTM)
vs sector
8.55
20.94
Total Debt to Equity (MRQ)
vs sector
13.77
15.47
LT Debt to Equity (MRQ)
vs sector
13.77
11.13
Return on Investment (TTM)
vs sector
56.70
13.00
Return on Equity (TTM)
vs sector
79.57
14.69

EXECUTIVE LEADERSHIP

Robert Chess
Independent Chairman of the Board, Since 2007
Salary: --
Bonus: --
Howard Robin
President, Chief Executive Officer, Director, Since 2007
Salary: $940,700.00
Bonus: $1,599,190.00
Gilbert Labrucherie
Chief Financial Officer, Senior Vice President, Since 2016
Salary: $607,400.00
Bonus: $531,475.00
John Nicholson
Chief Operating Officer, Senior Vice President, Since 2016
Salary: $625,800.00
Bonus: $547,575.00
Jillian Thomsen
Senior Vice President - Finance, Chief Accounting Officer, Since 2010
Salary: --
Bonus: --

COMPANY PROFILE

Sector: Healthcare
Industry: Biotechnology & Medical Research
Address:

455 Mission Bay Blvd S
SAN FRANCISCO   CA   94158-2158

Phone: +1415.4825300

Nektar Therapeutics is a biopharmaceutical company that discovers and develops medicines in areas of high unmet medical need. The Company's research and development pipeline of new investigational drugs includes treatments for cancer, auto-immune disease and chronic pain. It leverages its chemistry platform to discover and design new drug candidates. These drug candidates utilize its polymer conjugate technology platforms, which are designed to enable the development of new molecular entities that target known mechanisms of action. Its programs include Immuno-oncology (I-O), Immunology, Pain-NKTR-181 and Oncology-ONZEALD. It is developing medicines designed to directly or indirectly modulate the activity of key immune cells, such as cytotoxic T cells and Natural Killer (NK) cells, to increase their numbers and improve their function to recognize and attack cancer cells.

SPONSORED STORIES